On May, 9 The EPS for Endocyte, Inc. (ECYT) Expected At $-0.18

April 17, 2018 - By Benjamin Allen

During Q4 2017 the big money sentiment increased to 1.36. That’s change of 1.04, from 2017Q3’s 0.32. 11 investors sold all, 14 reduced holdings as Endocyte, Inc. ratio is positive. 15 increased positions while 19 funds took positions. Funds hold 19.91 million shares thus 140.76% more from 2017Q3’s 8.27 million shares.
Reilly Ltd Liability Company owns 2,000 shs. Weiss Asset Mgmt Limited Partnership invested 0.01% of its capital in Endocyte, Inc. (NASDAQ:ECYT). Leisure Capital has 28,304 shs. Partner Fund Mgmt Limited Partnership has 0.35% invested in Endocyte, Inc. (NASDAQ:ECYT) for 3.44M shs. Perceptive Limited accumulated 1.45 million shs. Hilltop Inc holds 0.01% of its capital in Endocyte, Inc. (NASDAQ:ECYT) for 10,720 shs. Renaissance Technology Limited Liability Company has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Comml Bank Of Mellon Corp, a New York-based fund reported 51,313 shs. Prelude Cap Management Limited Company holds 0.01% or 42,658 shs in its capital. 106,641 are held by Jacobs Levy Equity. Blackrock reported 1.14M shs or 0% of all its holdings. Manufacturers Life Insur The holds 0% of its capital in Endocyte, Inc. (NASDAQ:ECYT) for 1,801 shs. Bessemer Grp Incorporated reported 1,500 shs or 0% of all its holdings. D E Shaw And holds 0.01% of its capital in Endocyte, Inc. (NASDAQ:ECYT) for 2.08 million shs. Fmr Limited Liability Co reported 2.10M shs.

Endocyte, Inc. had 1 insider sale and 0 insider buys since March 9, 2018. This’s net activity of $45,677.

Earnings report for Endocyte, Inc. (NASDAQ:ECYT) is expected On May, 9., according to Faxor. Last year’s EPS was $-0.27, while now analysts expect change of 33.33 % up from current $-0.18 EPS. Analysts at Wall Street see Endocyte, Inc.’s 0.00 % EPS growth compared to $-0.18 EPS for last quarter. ECYT reached $9.23 on during the last trading session after $0.29 change.Currently Endocyte, Inc. is uptrending after 296.90% change in last April 17, 2017. ECYT has also 956,537 shares volume. The stock outperformed the S&P 500 by 285.35%.

Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage

Total analysts of 3 have positions in Endocyte (NASDAQ:ECYT) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 27, 2018 according to StockzIntelligence Inc Endocyte has 3 analyst reports. The company rating was upgraded by Cowen & Co on Tuesday, February 27.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.The firm is worth $636.59 million. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents.Currently it has negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.